The influence of menaquinone-7 on leukocyte and CD4+ transcriptomes in ulcerative colitis: a randomized controlled trial

The influence of menaquinone-7 on leukocyte and CD4+ transcriptomes in ulcerative colitis: a randomized controlled trial - LETRUC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00030783

Enrollment

Registered

2023-01-18

Start date

2023-01-25

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K51

Interventions

Group 1: Placebo Group 2: 150 microgram of vitamin K2 as menaquinone-7 daily, orally Group 3: 300 microgram of vitamin K2 as menaquinone-7 daily, orally

Eligibility

Sex/Gender

All

Age

10 Years to No maximum

Inclusion criteria

Inclusion criteria: The diagnosis of ulcerative colitis, no antivitamin K treatment, no supplementation of vitamin K. Inclusion criteria for the control group: no diseases, current medication use, no antivitamin K treatment, no supplementation of vitamin K.

Exclusion criteria

Exclusion criteria: Exclusion criteria for patients with ulcerative colitis: allergy to components of the tablets, pregnancy.

Design outcomes

Primary

Measure	Time frame
Gene expression in CD4+ T cells and in leukocytes	—

Secondary

Measure	Time frame
Qualitative and quantitative changes in fecal microbiota ; vitamin K status ; inflammatory markers ; PUCAI (Pediatric Ulcerative Colitis Activity Index) and its items	—

Countries

Poland

Contacts

Public ContactJan Nowak

Department of Pediatric Gastroenterology and Metabolic DiseasesPoznan University of Medical Sciences

pedgastro@ump.edu.pl+48618491432

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026